Balance Sheet Information (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
|---|
| Balance Sheet Related Disclosures [Abstract] |
|
| Schedule of cash and cash equivalents and restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
7,951,650 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,150 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
7,955,800 |
|
|
$ |
6,013,816 |
|
|
| Schedule of restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
7,951,650 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,150 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
7,955,800 |
|
|
$ |
6,013,816 |
|
|
| Schedule of prepaid expenses and other current assets |
Prepaid expenses and other current assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
December 31, 2022 |
| Prepaid Insurance |
$ |
112,307 |
|
|
$ |
117,315 |
|
| Prepaid Research and Development |
86,352 |
|
|
128,429 |
|
| Other |
67,841 |
|
|
97,325 |
|
| Total Prepaid Expenses and Other Current Assets |
$ |
266,500 |
|
|
$ |
343,069 |
|
|
| Schedule of accrued expenses |
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
December 31, 2022 |
| Payroll and Benefits |
$ |
1,051,087 |
|
|
$ |
1,312,443 |
|
| Professional Fees |
93,684 |
|
|
282,721 |
|
| Clinical Trials |
209,653 |
|
|
57,020 |
|
| Other |
44,610 |
|
|
183,750 |
|
| Total Accrued Expenses |
$ |
1,399,034 |
|
|
$ |
1,835,934 |
|
|